Advertisement
Product › Details
selumetinib (AZD6244 / ARRY-142886)
Next higher product group | MEK inhibitor | |
Status | 2005-06-09 development existent | |
Organisation | AstraZeneca (Group) | |
Organisation 2 | Array BioPharma Inc. (Nasdaq: ARRY) | |
Group | Pfizer (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for MEK inhibitor
- [1] ADC Therapeutics S.A.. (3/19/20). "Press Release: ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company". Lausanne....
- [2] Boehringer Ingelheim. (10/29/19). "Press Release: Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing". Ingelheim....
- [3] Boehringer Ingelheim. (9/4/19). "Press Release: Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound". Ingelheim & Mumbai....
- [4] Novartis AG. (8/29/18). "Press Release: European Commission Approves Novartis Combination Therapy Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600 Mutation-positive Melanoma". Basel....
- [5] AstraZeneca plc. (2/15/18). "Press Release: Selumetinib Granted Orphan Drug Designation by the US FDA for Neurofibromatosis Type 1"....
- [6] Novartis AG. (10/23/17). "Press Release: Novartis Combination Adjuvant Therapy Tafinlar + Mekinist Receives FDA Breakthrough Therapy Designation for Stage III BRAF V600 mutation-positive melanoma patients". Basel....
- [7] Novartis AG. (4/3/17). "Press Release: Novartis Drug Combination Tafinlar + Mekinist Receives EU Approval for BRAF V600-positive Advanced Non-small Cell Lung Cancer (NSCLC)". Basel....
- [8] Novartis AG. (2/24/17). "Press Release: Novartis Receives Positive CHMP Opinion for Tafinlar + Mekinist in BRAF-positive Non-small Cell Lung Cancer (NSCLC) Patients". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top